Specifications TableSubjectMedicineSpecific subject areaCancer research, Pharmacology and ToxicologyType of dataGraph\
Figure\
Time course of tumour growth\
Overall survival\
Western blotHow data were acquiredTumour growth was monitored by external measurement using calipers.\
WB images were acquired with an Epson 3200 scanner.\
Densitometric analysis was performed using ImageJ.Data formatRaw and analysed dataParameters for data collectionSubcutaneous experiments: mice were treated with 100 μl of saline (Control) or Cla (15 mg kg^−1^) by oral gavage for 2 weeks daily, starting 1 week after cell inoculum. Experimental groups comprised: control group, n = 4 mice (n = 8 tumour masses); Cla-administered group, n = 5 mice (n = 10 tumour masses).\
Survival experiments: mice were treated as above. Each experimental group comprised n = 10 mice.Description of data collectionTumour growth was monitored by external measurement using calipers. The volume of tumour masses measured at sacrifice (3 weeks after inoculum) was calculated by applying the ellipsoid equation, while during the experiment it was estimated with the following equation: 0.5 x Length x Width^2^.\
Whole protein lysates were obtained from a portion of excised tumour masses at sacrifice. Samples were homogenized in cold protein extraction buffer and sonicated for 30 min.\
Survival was monitored until death.Data source locationDepartment of Experimental and Clinical Medicine, University of Florence, Florence, ItalyData accessibilityWith the article**Value of the data**•The *in vivo* effect of Clarithromycin has been previously described for different cancer model, except for Colorectal Cancer.•This research analysed the *in vivo* effect of Clarithromycin in two different xenograft models of Colorectal Cancer: with the subcutaneous model we provide new insights about the effect of the drug on both tumour growth and expression of autophagic and apoptotic proteins; with the intraperitoneal model we evaluated the overall survival and the toxicity of the drug.•Valuable for researchers interested in the impact of Macrolide Antibiotics on Cancer treatment.

1. Data {#sec1}
=======

The *in vivo* efficacy of Cla was evaluated in two preclinical CRC xenograft models, both employing human CRC cells: HCT116 cells xenografted subcutaneously, and LS174T cells injected intraperitoneally. In both cases, immunodeficient mice were used. Compared to the control group, the volumes of the subcutaneous tumours were significantly (*P* = 0.0001) reduced after 2 weeks of Cla treatment (15 mg Kg^−1^, daily, by oral gavage) ([Fig. 1](#fig1){ref-type="fig"}A). The same treatment schedule produced a significant increase of the overall survival of LS174T-injected mice ([Fig. 1](#fig1){ref-type="fig"}B) (*P* = 0.0355), without inducing toxicity. No death or significant body weight change was observed in Cla-treatment group ([Fig. 1](#fig1){ref-type="fig"}C).Fig. 1**Efficacy of Clarithromycin in two xenograft models of Colorectal Cancer.** (**A**) Time course of tumour growth in control and Cla (15 mg Kg^−1^) treated nude mice, subcutaneously (s.c.) injected with HCT116 cells (3 × 10^6^/flank). Seven days after the inoculum, mice were treated with saline (control) and Cla. Cla was daily administered by oral gavage (o.g.) for 14 days, as reported in the schematic representation of treatment regime. Data presented as mean ± SEM of 8 masses for control group (*n* = 4 mice) and 10 masses for Cla group (*n* = 5 mice). \*\*, *P* = 0.0001 (Student\'s t-test). (**B**) Nude athimic mice were injected with LS174T cells (10 × 10^6^ cells i.p.) and starting from day 7, animals were treated daily with saline (control, *n* = 10) and Cla (15 mg kg^−1^, by o.g., *n* = 10), as reported in the schematic representation of treatment regime. Survival curves of each experimental group, estimated by Kaplan and Meier analysis are reported. \*, *P* = 0.0355 (Gehan-Breslow-Wilcoxon Test). (**C**) Body weight of LS174T xenograft-bearing nude mice, treated as in (B). Data presented as mean ± SEM (*n* = 10 mice for each treatment group). *ns* = not significant (Student\'s t-test).Fig. 1

Two weeks after treatment with Cla, mice subcutaneously injected with HCT116 were sacrificed, and tumour masses were collected, in order to analyse the effects of the drug on the autophagic process studying the expression of two autophagic markers: (1) the conversion of the soluble form of the microtubule-associated protein 1-light chain 3 (LC3-I), to the lipidated autophagosome-associated form, LC3-II, and (2) the ubiquitin-binding protein p62/sequestome 1 (p62/SQSTM1) [@bib1]. Compared to control, the LC3-II/LC3-I ratio was significantly increased and the p62/SQSTM1 levels were significantly decreased in Cla-treated tumours ([Fig. 2](#fig2){ref-type="fig"}A). Then we studied the activation of caspase 3 in tumour masses, as a marker of apoptosis induction [@bib2]. Significant reduction in protein levels of pro-caspase 3, correlated to increase in cleaved (activated form) caspase 3, was detected in the tumour masses of Cla-treated group ([Fig. 2](#fig2){ref-type="fig"}A). Finally, phosphorylation of Erk 1/2 and Akt, pathways involved both in the modulation of autophagic [@bib3], [@bib4], [@bib5], [@bib6] and apoptotic processes [@bib6], [@bib7], was significantly inhibited by Cla treatment ([Fig. 2](#fig2){ref-type="fig"}B).Fig. 2**Clarithromycin-induced modulation of markers of autophagy and apoptosis in tumour masses.** (**A-B**) WB analysis of the protein levels of phospho-ERK1/2^Thr202/Tyr204^, phospho-Akt^Thr308^, pro-caspase 3, cleaved caspase 3, LC3 and p62/SQSTM1 in the total lysates of HCT116 tumour xenografts of mice treated as in ([Fig. 1](#fig1){ref-type="fig"}A). The membranes were reprobed with anti-ERK1/2, anti-Akt or anti-tubulin antibodies. The corresponding densitometric results are given in the bar graphs; data shown as mean ± SEM (*n* = 4 different tumour masses for each treatment group). \*, *P* \< 0.05 (Student\'s t-test).Fig. 2

2. Experimental design, materials, and methods {#sec2}
==============================================

2.1. *In vivo* tumour xenograft models {#sec2.1}
--------------------------------------

Mice experiments were performed at the Laboratory of Genetic Engineering for the Production of Animal Models (LIGeMA) at the Animal House of the University of Florence (Ce.S.A.L.). Mice were housed in filter-top cages with a 12-h dark-light cycle, and had unlimited access to food and water. Procedures were conducted according to the laws for experiments on live animals (Directive 2010/63/EU), and approved by the Italian Ministry of Health (authorization n° 114/2016-PR and n° 1279/2015-PR).

For subcutaneous xenografts, female nude mice (Envigo Laboratories) aged five to six weeks were injected subcutaneously in either flanks with 3 × 10^6^ HCT116 cells, resuspended in 100 μl complete medium. After cell inoculation, mice were monitored daily to ensure they did not show any signs of suffering or disease (such as weight loss, abdominal distension, impaired movement, edema in the injection area). Mice were treated with 100 μl of saline or Cla (15 mg kg^−1^) by oral gavage (o.g.) for two weeks daily, starting one week after inoculation. Experimental groups comprised: control group, *n* = 4 mice (*n* = 8 tumour masses); Cla-administered group, *n* = 5 mice (*n* = 10 tumour masses). Tumour growth was monitored by external measurement using calipers. The volume of tumour masses measured at sacrifice (3 weeks after inoculum) was calculated by applying the ellipsoid equation, while during the experiment it was estimated with the following equation: 0.5 x Length x Width^2^.

For survival experiments, female nude mice aged five to six weeks were injected intraperitoneally (i.p.) with 10^7^ LS174T cells, resuspended in 100 μl EMEM plus 20% Matrigel (20 mg/ml). Mice were treated with 100 μl of saline or Cla (15 mg kg^−1^) by o.g. daily, starting one week after inoculation, and survival was monitored until death. Each experimental group comprised *n* = 10 mice.

2.2. Western blot (WB) analysis {#sec2.2}
-------------------------------

For tumour lysates, whole protein lysates were obtained from a portion of excised tumour masses from mice injected with HCT116 cells. Samples were homogenized in cold protein extraction buffer (1X Cell Lysis Buffer; Cell Signaling Technology, \#9803) and sonicated for 30 min.

The following primary antibodies were used for WBs, at the indicated concentrations. The rabbit pAb against LC3A/B (\#4108; dilution 1:1000), the rabbit mAb against SQSTM1/p62 (clone D5E2, \#8025; dilution 1:1000), the rabbit mAb against Caspase 3 (clone 8G10, \#9665; dilution 1:1000), and the rabbit pAb against phospho-44/42 MAPK (Erk1/2) (Thr202/Tyr204, \#9101; dilution 1:1000) were purchased from Cell Signaling Technology. The mouse mAb against phospho-AKT1/2/3 (clone B-5, sc-271966; dilution 1:500), the rabbit pAb against AKT1/2/3 (clone H-136, sc8312; dilution 1:500), and the rabbit pAb against ERK1/2 (clone H-72, sc-292838; dilution 1:200) were purchased from Santa Cruz Biotechnology. The anti-α-tubulin mouse mAb (T9026; dilution 1:500) was used as loading control. Anti-rabbit IgG peroxidase-conjugated (A0545; dilution 1:10000) and anti-mouse IgG peroxidase antibodies (A4416; dilution 1:5000) were used as secondary antibodies.

WB images were acquired with an Epson 3200 scanner. Densitometric analysis was performed using ImageJ on two different scans, after background subtraction, from at least three different experiments, as previously described [@bib8].

2.3. Statistical analysis {#sec2.3}
-------------------------

Data are given as mean values ± standard error of the mean (SEM). The number of independent experiments is indicated in the Figure legends as *n*. Statistical comparisons were performed with GraphPad Prism 6.0e (GraphPad Software, San Diego, USA). Unless otherwise indicated, for comparisons between Cla-treated and Control group, we used Student\'s t-test and *P* values are reported as \*, *P* \< 0.05.
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